Pricing
  1. US-listed companies
  2. Panbela Therapeutics, Inc.
  3. Financials
  4. Cash from financing

Panbela Therapeutics, Inc.【PBLA】

Market cap
$63.36K
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 202326+388.27%
Dec 31, 20225-46.96%
Dec 31, 202110-3.34%
Dec 31, 202010+176.00%
Dec 31, 20194+3.87%
Dec 31, 20184+17.29%
Dec 31, 20173+62.19%
Dec 31, 20162-28.41%
Dec 31, 20153-32263.04%
Dec 31, 2014-0-28.37%
Dec 31, 2013-0-269.48%
Dec 31, 20120

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)